Aspirin Doesn't Prevent Breast Cancer
Long-Term Aspirin, Ibuprofen May Slightly Raise Risk, New Research Shows
May 31, 2005 -- What a difference a year makes. A study released last May made national headlines with the finding that breast cancer among women who take aspirin or ibuprofen.
Now a new study shows little protective benefit and a possible increase in
Researchers downplayed the potential risk but called the failure to find a protective benefit for the anti-inflammatory pain relievers disappointing.
"These drugs are not preventing breast cancer as earlier studies suggested that they might," Sarah F. Marshall of the University of Southern California, Los Angeles, tells WebMD. Mixed Findings for Daily Use
Marshall and colleagues analyzed data on more than 114,000 California women. None of the women had breast cancer when they entered the study, but nearly 2,400 were diagnosed with the disease between 1995 and 2001.
Their findings are reported in the June 1 issue of The Journal of the National Cancer Institute.
The researchers reported that taking aspirin or ibuprofen more than once a week but not every day neither increased nor decreased breast cancer risk. Other anti-inflammatory drugs, such as naproxen, were not studied.
Daily aspirin use for more than five years, however, was linked to a small increased risk for developing breast cancers called hormone receptor-negative tumors. Breast cancers are classified based on whether or not they grow in response to hormones, such as estrogen. Tumors that do not respond to hormones -- hormone receptor-negative -- are less common and harder to treat.
But the risk from daily aspirin use is small. The researchers say that among the nearly 2,400 women with breast cancer, seven excess cases of hormone receptor-negative cancer may be caused by long-term daily aspirin use. The study did not compare the risks of low-dose "baby" 81 milligram aspirin to the regular 325 milligram dose.
Small Risk With Ibuprofen
Daily ibuprofen use was also linked to an increase in breast cancer risk among women in the study. The risk was higher for women with tumors that had spread to other parts of the body.